Guardant Health (GH) director receives 264 shares from RSU vesting award

Rhea-AI Filing Summary

Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units on February 21, 2026. These units, granted on November 8, 2024, convert into common stock at no cost as part of a four-year equity award vesting schedule.

Insider Trade Summary

264 shares exercised/converted

Mixed 2 txns

Insider MIGNONE ROBERTO

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	264	$0.00	--
Exercise	Common Stock	264	$0.00	--

Holdings After Transaction: Restricted Stock Units — 8,448 shares (Direct); Common Stock — 4,223 shares (Direct)

Footnotes (1)

1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter. Not applicable for Restricted Stock Units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MIGNONE ROBERTO

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/21/2026		M		264	A	$0	4,223	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/21/2026		M			264	(1)	(2)	Common Stock	264	$0	8,448	D

Explanation of Responses:

1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Roberto A. Mignone	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Guardant Health (GH) disclose for Roberto Mignone?

Guardant Health disclosed that director Roberto Mignone acquired 264 shares through the vesting and conversion of restricted stock units. These RSUs are part of an equity award that settles into common stock at no cash cost to him as they vest over time.

How many Guardant Health (GH) restricted stock units vested for Roberto Mignone?

A total of 264 restricted stock units vested for Roberto Mignone. Each unit represents a right to receive one share of Guardant Health common stock, and they converted into shares at a price of $0.0000 per share as part of his compensation package.

What is the vesting schedule for Roberto Mignone’s November 8, 2024 RSU grant at GH?

The RSU grant dated November 8, 2024 vests over four years. 25% vested on the one-year anniversary of October 21, 2024, and the remaining 75% vests in equal monthly installments over the following three-year period, subject to continued service.

Did Roberto Mignone buy Guardant Health (GH) shares on the open market?

No, the filing shows an exercise or conversion of derivative securities, not an open-market purchase. The 264 shares came from restricted stock units that settled into common stock at a stated price of $0.0000 per share under his equity award.

How did Roberto Mignone’s Guardant Health share holdings change after this Form 4?

Following the RSU conversion, one line in the filing shows 4,223 common shares held directly. Another line shows 8,448 restricted stock units remaining. These figures reflect his reported direct equity interests after the February 21, 2026 transactions.